Meredith Pelster
机构：Sarah Cannon Research Institute, Sarah Cannon, Tennessee Oncology
发表论文 16 篇 · 总被引 34 次 · h-index 2
代表论文
- Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer (2026 · New England Journal of Medicine · 被引 31)
- Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC). (2026 · Journal of Clinical Oncology · 被引 2)
- Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer (2026 · Nature Medicine · 被引 1)
- Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-line Therapy for Advanced Colorectal Adenocarcinoma: The Phase II DeFianCe Trial (2026 · Clinical Cancer Research)
- ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors. (2026 · Journal of Clinical Oncology)
- A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA–positive colorectal cancer. (2026 · Journal of Clinical Oncology)